ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-Claudin 18.2 Antibody-drug Conjugate ASP546C

Also written as “XNW27011” and “ASP546C”.

Its studies are mostly in Adenocarcinoma · Lung Neoplasms, led by Astellas Pharma.

Furthest: phase 2, since Dec 25, 20242 company-led studies, 2 open or runningNext primary completion: Dec 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma22 open or runningphase 2since Dec 25, 2024Dec 25, 2024Dec 30, 2026phase 2 · NCT06792435

Also a collaborator on its studies: Evopoint Biosciences.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 25, 2024First study: phase 2 study in Lung NeoplasmsFirst studyNCT06792435 · 240 enrolled · China
  2. Mar 18, 2026Phase 2 study in AdenocarcinomaNCT07488676 · 150 planned · United States, Japan

Ahead

  1. Dec 30, 2026Primary completion: phase 2 study in Lung NeoplasmsNCT06792435
  2. Jul 31, 2029Primary completion: phase 2 study in AdenocarcinomaNCT07488676

TargetBeta

CLDN18 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) ”NCIt, by rule

Other programs on CLDN18

ProgramCompanyFurthest phaseStudies
zolbetuximabruleAstellas Pharmaphase 412
sonesitatug vedotinAstraZenecaphase 37
garetatug rezetecanJiangsu HengRui Medicinephase 37
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905ruleQilu Pharmaceuticalphase 36
tecotabart vedotinSino Biopharmaceuticalphase 36
arcotatug tavatecanruleInnovent Biologicsphase 35
terallethrinruleFutureGen Biopharmaceutical (Beijing)phase 33
Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1biokin-shanghai-biopharmaceutical-co-ltdphase 33
emaretamigruleAstellas Pharmaphase 33
Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200ruleSichuan Kelun Pharmaceuticalphase 23
givastomigrulei-mab-biopharma-us-limitedphase 22
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863AstraZenecaphase 21

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07488676Adenocarcinoma · United States, Japan2RecruitingJul 31, 2029150
NCT06792435Lung Neoplasms · China2Active, not recruitingDec 30, 2026240

How it is read

Names in the registry

  • “XNW27011”, 2 entries
  • “ASP546C”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.